Genasense gets standard review for CLL

Genta's Genasense (oblimersen) has a standard review PDUFA date of Oct. 28 for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), Genta says March 1. The review designation comes despite Genta's request for a priority review of its NDA, which it submitted Dec. 29, 2005 (1Pharmaceutical Approvals Monthly January 2006, p. 26). The firm highlighted the submission as "the first NDA for a drug that promotes chemotherapy-induced apoptosis in hematologic oncology." Genasense is a first-in-class Bcl-2 protein inhibitor. One of Genta's long-term goals for Genasense is to expand the agent's indications into first-line CLL...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet